Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 11-12, 2016, Pages 1183-1198

  Harrison, S A ^a   Marri, S R ^a   Chalasani, N ^a   Kohli, R ^a   Aronstein, W ^a   Thompson, G A ^a   Irish, W ^a   Miles, M V ^a   Xanthakos, S A ^a   Lawitz, E ^a   Noureddin, M ^a   Schiano, T D ^a   Siddiqui, M ^a   Sanyal, A ^a   Neuschwander Tetri, B A ^a   Traber, P G ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBOHYDRATE DERIVATIVE; CYTOKERATIN 18; GALECTIN 3; GAMMA GLUTAMYLTRANSFERASE; GR MD 02; HAPTOGLOBIN; PLACEBO; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GALACTOARABINO-RHAMNOGALATURONAN; PECTIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BENIGN TUMOR; BURSITIS; CHEST TIGHTNESS; CLINICAL ARTICLE; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; ECHOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTION; EXPLORATORY RESEARCH; FEMALE; FIRST IN HUMAN STUDY; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HEPATOGRAPHY; HUMAN; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; JOINT SWELLING; KIDNEY DISEASE; LABORATORY TEST; LEAN BODY WEIGHT; LIMB PAIN; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; METABOLIC DISORDER; MULTIPLE DRUG DOSE; MUSCULOSKELETAL DISEASE; MYALGIA; NAIL COLOR DEFECT; NEUROLOGIC DISEASE; NONALCOHOLIC FATTY LIVER; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STREPTOCOCCAL PHARYNGITIS; SWELLING; THORAX DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE ODOR; VITAL SIGN; VOLUME OF DISTRIBUTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADULT; AGED; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; GALECTIN 3; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PECTINS;

EID: 84995784051     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13816     Document Type: Article

References (28)

1. DiLella S, Sundblad V, Cerliani JP, et al. When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry 2011; 50: 7842–57.
2. Henderson NC, MacKinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006; 103: 5060–5.
3. MacKinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 2012; 185: 537–46.
4. Henderson NC, MacKinnon AC, Farnworth SL, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288–98.
5. Iacobini C, Menini S, Ricci C, et al. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol 2011; 54: 975–83.
6. Nomoto K, Nishida T, Nakanishi Y, et al. Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. ScientificWorldJournal 2012; 2012: 959824.
7. Nomoto K, Tsuneyama K, Abdel Aziz HO, et al. Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 2006; 210: 469–77.
8. Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML, Pejnovic N. Galectin-3 ablation enhances liver steatosis, but attenuates Inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis. Mol Med 2015; 21: 453–65.
9. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS ONE 2013; 8: e83481.
10. Traber PG, Chou H, Zomer E, et al. Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease. PLoS ONE 2013; 8: e75361.
11. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726–32.
12. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010; 7: 195–203.
13. Jusko WJ. Guidelines for the collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Spokane, WA: Applied Therapeutics Inc, 1986; 9–54.
14. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1975.
15. Wagner JG. Drug accumulation. J Clin Pharmacol J New Drugs 1967; 7: 84–8.
16. Kohli R, Kirby M, Xanthakos SA, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 2010; 52: 934–44.
17. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454–62.
18. Yilmaz Y, Eren F, Kurt R, et al. Serum galectin-3 levels in patients with nonalcoholic fatty liver disease. Clin Biochem 2011; 44: 955–8.
19. Weigert J, Neumeier M, Wanninger J, et al. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1404–11.
20. Karsdal MA, Krarup H, Sand JM, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases – early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014; 40: 233–49.
21. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.
22. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675–83.
23. Ratziu V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006; 6: 6.
24. Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol 2012; 57: 541–8.
25. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994; 39: 2426–32.
26. Ho AS, Cheng CC, Lee SC, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010; 17: 58.
27. Rehman AA, Ahsan H, Khan FH. Alpha-2-Macroglobulin: a physiological guardian. J Cell Physiol 2013; 228: 1665–75.
28. Menke T, Niklowitz P, de Sousa G, Reinehr T, Andler W. Comparison of coenzyme Q10 plasma levels in obese and normal weight children. Clin Chim Acta 2004; 349: 121–7.